Wang, Dongdong published the artcileCyclosporin population pharmacokinetics in pediatric refractory nephrotic syndrome based on real-world studies: effects of body weight and spirolactone administration, Recommanded Product: 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, the main research area is refractory nephrotic syndrome cyclosporin spirolactone body weight pharmacokinetics pediatrics; cyclosporin; pediatric refractory nephrotic syndrome; population pharmacokinetics; real-world study; spirolactone; weight.
Different models of population pharmacokinetics (PPK) of cyclosporin have been established in various populations. However, the cyclosporin PPK model in patients with pediatric refractory nephrotic syndrome (PRNS) has yet to be constructed. The present study aimed to establish the cyclosporin PPK model in PRNS, and to identify factors that may account for any variability. Chinese patients with PRNS treated with cyclosporin between June 2014 and June 2018 at the Children’s Hospital of Fudan University (Shanghai, China) were retrospectively analyzed. The impact of demog. features, laboratory parameters and concomitant medications was evaluated. A total of 18 PRNS patients from real-world studies were analyzed by non-linear mixed-effects modeling. A one-compartment model with first-order absorption and elimination was selected as the appropriate model in PRNS. Body weight (WT) and spirolactone intake were included as significant covariates for the apparent oral clearance (CL/F), and the WT was revealed to significantly influence the apparent volume of distribution (V/F). The final covariate models were as follows: CL/F = 80.7 × (WT/70)0.75 × (1-0.265 × θspirolactone), and V/F = 2,030 × (WT/70), where θspirolactoneis the coefficient of spirolactone. The inter-individual variability in CL/F and V/F was 44.6 and 53.1%, resp. In conclusion, in the present study, a cyclosporin PPK model for patients with PRNS was successfully constructed, and the presence of a clin. significant interaction between spirolactone and cyclosporin in PRNS patients was determined based on real-world studies, indicating that concomitant medication with spirolactone was able to reduce cyclosporin clearance in the patients with PRNS.
Experimental and Therapeutic Medicine published new progress about Body weight. 72509-76-3 belongs to class pyridine-derivatives, name is 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C18H19Cl2NO4, Recommanded Product: 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate.